戻る Agenda
Session 9: Considerations for Medication Error Pharmacovigilance
Session Chair(s)
Jo Wyeth, PHARMD
Associate Director for Postmarket Assessments, OMEPRM, OSE, CDER, FDA, United States
Medication errors have a significant public health burden. This session will discuss the impact of medication errors, current state of medication error pharmacovigilance, and propose directions for building a pharmacovigilance medication error program for the future.
Learning Objective :
At the conclusion of this session, participants should be able to:
- Recognize that medication error prevention requires a collaborative effort among regulators, industry, patients, healthcare providers, and other stakeholders
- Identify differences and challenges in the approach for medication error pharmacovigilance versus adverse event pharmacovigilance
- Describe current and emerging approaches for surveilling medication errors
Speaker(s)
Christina Michalek, RPH
Medication Safety Specialist, Institute for Safe Medication Practices , United States
Medication Errors: Impact on the Victims
Reema Mehta, PHARMD, MPH
Senior Director, Head of Risk Management and Safety Surveillance Research, Pfizer Inc, United States
Speaker
Jo Wyeth, PHARMD
Associate Director for Postmarket Assessments, OMEPRM, OSE, CDER, FDA, United States
Roadmap for Medication Error Pharmacovigilance
Allan Fong, MS
Research Scientist and Data Scientist, Medstar Health National Center For Human Factors In Healthcare, United States
Natural Language Processing and Machine Learning with Patient Safety Event Reports
Lubna Merchant, PHARMD, MS
Risk Management Strategy, AbbVie, United States
Panelist